National Advertising Division of the National Better Business Bureau upholds Biotivia against complaint made by competing Resveratrol supplier

Although resveratrol is the trendiest new longevity compound, it alone will not address your entire need for advanced nutrition; hence Bio Quench and Bio Span+ were developed.

• Biotivia's Advertiser's Statement published in the NAD decision
  Biotivia is very pleased and gratified that NAD has chosen to uphold the company's web site, label and advertising claims either in full or with relatively minor or technical qualifications consistent with NAD's mission to insure that the message delivered by advertisers to their consumers is clear and free of statements that might be misinterpreted by the consumer.
   
• Enhanced bioavailability claim
  Biotivia has been sustained in its claim of enhanced bioavailability. The results of extensive product development confirmed by human trials clearly show a mean improvement of 1.88 times, to a maximum improvement of 2.27 times compared to reference standard purified transresveratrol, as determined using the HPLC method of measurement. Biotivia agrees entirely with NAD's clarification which confirms that enhanced bioavailability claims made for Bioforte and Transmax apply specifically to a comparison of its resveratrol to the reference standard, purified lab-grade resveratrol.
   
• Quercetin issue
  Biotivia agrees that the issue of quercetin's effect on bioavailability of resveratrol in humans is complex and accepts the decision of NAD but with important qualifications. The study referenced by Longevinex upon which their complaint is based has been refuted by multiple later, more comprehensive studies which seriously question the advisability of inhibiting resveratrol metabolites. In any event Biotivia recognizes that this issue requires further investigation prior to establishing definitive conclusions as to quercetin's effect on bioavailability and will in future only state that Quercetin inhibits the metabolites a fact with which Longevinex agrees.
   
• Sirt1 Activation Claim
  Biotivia is pleased that NAD did not contest the claim that quercetin inhibits Sirt1 gene activation. Biotivia submitted the authoritative evaluation of quercetin done in 2006 which concluded that quercetin did not stimulate SIRT1 genes but actually inhibited it transcription.
   
• Resveratrol stability (shelf life)
  Biotivia agrees with NAD that shelf life claims regarding resveratrol apply to the compound itself not to any specific product. The most recent and authoritative study on the subject actually concluded that the shelf life of resveratrol supplements was at least 48 months even under harsh environmental conditions.
   
• Biotivia supplies Transmax and Bioforte to research institutions and conducts studies of resveratrol's physiological effects. Again, Biotivia is satisfied that NAD has upheld its claim that Biotivia products are being supplied to researchers and universities for use in important human and animal trials. Biotivia has also provided both raw material and finished product in the form of Bioforte and Transmax to researchers at US universities and public and private research labs including, but not limited to Columbia University, Woods Hole Marine Biology Laboratory, Harvard University, the University of Pittsburg, the University of Montreal, and many others. Consequently no further action is required on the part of Biotivia as the company already complies with the position of NAD on this issue.
   
• CGMP manufacturing claim
  Biotivia is pleased that NAD agrees that Biotivia manufacturers its products in accordance with FDA CGMP standards. Biotivia points out that its manufacturing facility possesses a valid, current GMP certificate issued by the Health Ministry pursuant to its authority from the US FDA to do so and is subject to frequent and unannounced inspections. Biotivia products are also inspected by the FDA upon importation to the US. Biotivia understands that the FDA itself does not certify facilities as CGMP. Such certifications are issued by third parties. Therefore Biotivia has amended its site text to reflect this fact and has removed references to FDA certified CGMP and substituted the term, Made in accordance with FDA CGMP standards.
  In summation Biotivia is extremely heartened that NAD has sustained its claims with respect to the outstanding quality, unique advantages and documented benefits of Bioforte and Transmax and is more than willing to implement the suggested clarifications noted in their final decision.
  
  Biotivia is happy to provide our customers and site visitors with the entire text of the NAD decision. Such requests should be directed to Info@biotivia.com or to Mark Levine at the National Advertising Division of the Better Business Bureau at www.nad.bbb.org.